Bimiralisib’s oral and topical formulations are under clinical development for the treatment of Head and Neck Squamous Cell Carcinoma (oral) and Cutaneous T-Cell Lymphoma (topical). In addition, PIQUR has several other compounds in preclinical development and late-stage research in oncology, dermatology, CNS disorders and rare genetic diseases.
Head and Neck Squamous Cell Carcinoma
Oral bimiralisib has shown encouraging clinical activity and acceptable safety profile in Phase I/IIa studies in solid tumors and lymphomas.
Recent compelling data supported the initiation of a biomarker-driven (NOTCH1 LoF) phase II study in Head and Neck Squamous Cell Carcinoma (HNSCC). This study (PQR309-009) is currently ongoing. Clinical Trials
Cutaneous T-Cell Lymphoma
Topical bimiralisib is currently in clinical development for Cutaneous T-Cell Lymphoma.
Mechanism of Action
The PI3K-Akt-mTOR pathway is one of the three major cancer signalling pathways and plays a critical role in the regulation of cancer cell growth, survival, and proliferation. The deregulation of this pathway is initiated by genetic mutations and amplifications and is thought to be one of the most frequently mutated pathways in cancer.
PIQUR’s lead compound bimiralisib is a novel, potent small molecule with strong, balanced pan-PI3K/mTOR selectivity.
We have several other compounds in preclinical development and late-stage research in oncology, dermatology, CNS disorders and rare genetic diseases.
To fully exploit the potential of our drug candidates, we welcome strategic partnerships with renowned biotech and pharmaceutical companies.
PIQUR Therapeutics AG is a privately owned company that is backed by private investors and Versant Venture, a leading venture capital firm that specializes in investments in innovative biopharmaceuticals.